Wiki source code of Amgen Inc.

Last modified by Asif Farooqui on 2023/03/13 18:00
Show last authors
1 {{box cssClass="floatinginfobox" title="**Contents**"}}
2 {{toc/}}
3 {{/box}}
4
5 = Summary =
6
7 * Amgen is a leading biotechnology company.
8 * Amgen focuses on areas in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
9 * In 2022 Amgen acquired ChemoCentryx and Horizon .
10
11
12
13 [[image:AMGN0.png||height="186" width="722"]]
14
15
16 Amgen (Nasdaq: AMGN) is a leading biotechnology company. Amgen focuses on areas in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
17
18
19 = Recent Developments =
20
21 **Amgen announces Cardiovascular study to evaluate association between Lipoprotein(a) and Cardiovascular risk in African Americans**{{footnote}}https://investors.amgen.com/news-releases/news-release-details/amgen-announces-cardiovascular-study-evaluate-association{{/footnote}}
22
23 Feb. 22, 2023; Amgen announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), which will measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States. ASCVD is defined as the buildup of cholesterol plaque in arteries and includes events such as heart attack and stroke.
24
25
26 Cardiovascular disease is the number one killer of all Americans, and the cardiovascular risk for African Americans is even higher. According to the U.S. Department of Health and Human Services, African Americans are 30% more likely to die from heart disease than non-Hispanic whites.
27
28
29 **Amjevita™ (adalimumab-atto), first biosimilar to Humira®, now available in the United States**{{footnote}}https://investors.amgen.com/news-releases/news-release-details/amjevitatm-adalimumab-atto-first-biosimilar-humirar-now{{/footnote}}
30
31 Jan. 31, 2023; Amgen announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.
32
33
34 AMJEVITA (40 mg) is available at a list price (Wholesale Acquisition Cost) 55% below the current Humira list price. AMJEVITA is also available at a list price 5% below the current Humira list price. Amgen's goal is to provide broad access for patients by offering two options to health plans and pharmacy benefit managers.
35
36
37 Amgen currently has 11 biosimilar medicines in market or under development. Five are FDA-approved in the U.S. and three are approved in the European Union.
38
39
40 == Recent Acquisitions ==
41
42 On October 20, 2022, the company completed its acquisition of ChemoCentryx for $52.00 per share in cash totaling approximately $3.8 billion, net of cash acquired.
43
44
45 On December 12, 2022, the company announced that the company entered into a transaction agreement under which Amgen will acquire all shares of Horizon for $116.50 per share in cash for a transaction equity value of approximately $27.8 billion.
46
47
48 In March 2022, the company announced to build a drug substance plant in North Carolina that will increase its manufacturing network capacity.
49
50
51
52 [[image:AMGN1.jpg]]
53
54
55 = Financial Highlights =
56
57 For the full year ended December 31, 2022, total revenues increased 1% to $26.3 billion, resulting from a 2% increase in product sales driven by a 9% increase in volume, partially offset by 5% lower net selling price and 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues increased 3% for the full year.{{footnote}}https://investors.amgen.com/news-releases/news-release-details/amgen-reports-fourth-quarter-and-full-year-2022-financial{{/footnote}}
58
59
60 For the full year, GAAP EPS increased 18% from $10.28 to $12.11, primarily driven by the write-off of $1.5 billion in Acquired In-Process Research & Development (Acquired IPR&D) associated with its acquisition of Five Prime Therapeutics in 2021. GAAP operating income increased from $7.6 billion to $9.6 billion, and GAAP operating margin increased 7.2 percentage points to 38.6%.
61
62
63 non-GAAP EPS increased 27% from $13.92 to $17.69 driven by the write-off of $1.5 billion in Acquired IPR&D associated with its acquisition of Five Prime Therapeutics in 2021 and lower weighted-average shares outstanding in 2022. non-GAAP operating income increased from $10.5 billion to $12.8 billion, and non-GAAP operating margin increased 8.2 percentage points to 51.5%.
64
65
66 The Company generated $8.8 billion of free cash flow for the full year versus $8.4 billion in 2021.
67
68
69 Product sales for the full year increased 2% versus 2021, driven by 9% volume growth, partially offset by 5% lower net selling price and 2% negative impact from foreign exchange.
70
71
72
73 [[image:AMGN2.jpg]]
74
75
76
77 = Company Overview =
78
79 Amgen Inc. is a biotechnology company. The company works for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.{{footnote}}https://fintel.io/doc/sec-amgen-inc-318154-10k-2023-february-09-19397-2777{{/footnote}}
80
81 Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. AMGen has a presence in approximately 100 countries worldwide. Amgen operates in one business segment: human therapeutics.
82
83
84 == Products ==
85
86 Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options.{{footnote}}https://www.amgen.com/products{{/footnote}}
87
88
89 The company's principal products are ENBREL, Prolia, Otezla, XGEVA, Aranesp, Nplate, Repatha, KYPROLIS, Neulasta and EVENITY. The company also market a number of other products, including MVASI, Vectibix, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, Parsabiv, KANJINTI, LUMAKRAS/LUMYKRAS, TEZSPIRE, NEUPOGEN, Sensipar/Mimpara and TAVNEOS.
90
91
92
93 [[image:AMGN3.jpg]]
94
95
96 == Patents ==
97
98 The following table lists its outstanding patents.
99
100 * Enbrel (etanercept)
101 * Prolia /XGEVA (denosumab)
102 * Otezla (apremilast)
103 * Aranesp (darbepoetin alfa)
104 * Nplate (romiplostim)
105 * Repatha (evolocumab)
106 * KYPROLIS (carfilzomib)
107 * EVENITY (romosozumab-aqqg)
108 * BLINCYTO (blinatumomab)
109 * Aimovig (erenumab-aooe)
110 * Parsabiv (etelcalcetide)
111 * LUMAKRAS® /LUMYKRAS™(sotorasib)
112 * TEZSPIRE (tezepelumab-ekko)
113 * TAVNEOS (avacopan)
114
115
116
117 == Global Presence ==
118
119 Amgen has reached millions of patients around the world.{{footnote}}https://www.amgen.com/amgen-worldwide{{/footnote}}
120
121 * Australia
122 * Austria
123 * Belgium
124 * Brazil
125 * Bulgaria
126 * Canada
127 * China
128 * Colombia
129 * Croatia
130 * Czech Republic
131 * Denmark
132 * Europe
133 * Finland
134 * France
135 * Germany
136 * Greece
137 * Hong Kong
138 * Hungary
139 * Ireland
140 * Italy
141 * Japan
142 * Korea
143 * Mexico
144 * Netherlands
145 * Norway
146 * Poland
147 * Portugal
148 * Romania
149 * Russia
150 * Saudi Arabia
151 * Singapore
152 * Slovakia
153 * Slovenia
154 * Spain
155 * Sweden
156 * Switzerland
157 * Taiwan
158 * Thailand
159 * Türkiye
160 * United Kingdom
161 * United States
162
163
164
165 = Company History =
166
167 AMGen (Applied Molecular Genetics Inc.) is established in Thousand Oaks, California, on April 8, 1980, as the brainchild of venture capitalists William K. (Bill) Bowes and associates.{{footnote}}https://www.amgen.com/about/amgen-history{{/footnote}}
168
169
170 |**Year**|**Milestone**
171 |1980|Amgen Inc. was founded by George Rathmann, a former executive at Abbott Laboratories, and venture capitalist Gordon Binder. The company's name is derived from the words "applied molecular genetics."
172 |1982|Amgen Inc. raised $42 million in an initial public offering (IPO) and became a publicly traded company on the NASDAQ stock exchange.
173 |1983|Amgen Inc. received approval from the U.S. Food and Drug Administration (FDA) for its first product, Epogen (epoetin alfa), a treatment for anemia in patients with chronic kidney disease.
174 |1984|Amgen Inc. acquired Synergen Inc., a biotechnology company based in Colorado.
175 |1985|Amgen Inc. received approval from the FDA for Neupogen (filgrastim), a treatment for low white blood cell counts in cancer patients undergoing chemotherapy.
176 |1986|Amgen Inc. established a manufacturing facility in Thousand Oaks, California, which would become the company's headquarters.
177 |1990|Amgen Inc. acquired Immunex Corporation, a biotechnology company based in Seattle.
178 |1991|Amgen Inc. received approval from the FDA for Enbrel (etanercept), a treatment for rheumatoid arthritis.
179 |1998|Amgen Inc. acquired Tularik Inc., a biotechnology company based in California.
180 |2002|Amgen Inc. received approval from the FDA for Aranesp (darbepoetin alfa), a longer-lasting version of Epogen for the treatment of anemia.
181 |2006|Amgen Inc. acquired Abgenix Inc., a biotechnology company based in California.
182 |2009|Amgen Inc. acquired Alantos Pharmaceuticals, a biotechnology company based in Germany.
183 |2011|Amgen Inc. acquired BioVex Group Inc., a biotechnology company based in Massachusetts.
184 |2012|Amgen Inc. received approval from the FDA for Xgeva (denosumab), a treatment for bone metastases in cancer patients.
185 |2013|Amgen Inc. acquired Onyx Pharmaceuticals, a biotechnology company based in California.
186 |2020|Amgen Inc. announced that it would acquire Five Prime Therapeutics, a biotechnology company based in California.
187
188
189
190 References
191
192 {{putFootnotes/}}
This site is funded and maintained by Fintel.io